Opdyta 40mg injection | Apple pharmaceuticals (1)

1
Apple pharmaceuticals
Is a fully licensed and regulated pharmacy, takes
all precautions to strictly abide by the laws and
regulations set forth in the dispensing of
prescription medications. By placing the order
for your prescription medicines, you acknowledge
and accept the following terms regarding the
purchase of any prescription medicines.
2
Nivolumab injection
Opdyta 40mg
3
DESCRIPTION
Opdyta 40mg is prescription drug which is used
under supervision of doctor Opdyta 40mg belongs
to human monoclonal antibody which stops the
interaction between PD-1 and its ligands, PD-L1
and PD-L2. Opdyta 40mg is an IgG4 kappa
immunoglobulin which has a calculated molecular
mass of 146 kDa. It is expressed in a
recombinant Chinese Hamster Ovary (CHO) cell
line. Opdyta 40mg is also known as an immune
checkpoint inhibitor. Sometimes these drugs are
called targeted therapies because they target
specific proteins (receptors) on the surface of
cells.
4
INDICATION
Opdyta 40mg is indicated for the treatment of
patients having Melanoma Non-Small
Cell Lung Cancer Kidney (Renal Cell) Cancer
MECHANISM
Binding of these ligands to the PD-1 receptor
occur on T cells, prohibits T cell multiplication
and cytokine production. Upregulation of the PD-1
ligands occurs in some tumor and signallingvia
this pathway can provide to prohibition of active
T-cell immune surveillance of tumor. Nivolumab
belongs to human immunoglobulin G4 (IgG4)
monoclonal antibody which binds to the PD-1
receptor and stops its interaction with PD-L1 and
PD-L2, releasing PD-1 pathway-mediated prevention
of the immune response, containing the anti-tumor
immune response, resulting in reduced tumor
growth.
5
DOSAGE
Opdyta recommended dosage for unresectable or
metastatic melanoma As single agent is either
240mg every 2 weeks or 480mg every 4 weeks given
as IV infusion over 30 minutes until disease
progression or unacceptable toxicity With
ipilimumab The recommended dose of Opdyta is
1mg/kg administrated as an intravenous infusion
over 30 minutes, followed by ipilimumab 3mg/kg
given as IV over 90 minutes on the same day.
Duration 3 weeks of max 4 doses, after completing
combination dose continue the single agent
treatment For adjuvant treatment of melanoma
As single agent is either 240mg every 2 weeks or
480mg every 4 weeks given as IV infusion over 30
minutes until disease progression or unacceptable
toxicity for up to 1 year. For Non-small cell
lung cancer As single agent is either 240mg
every 2 weeks or 480mg every 4 weeks given as IV
infusion over 30 minutes until disease
progression or unacceptable toxicity. For small
cell lung cancer As single agent is either
240mg every 2 weeks given as IV infusion over 30
minutes until disease progression or unacceptable
toxicity for up to 1 year.
6
PREGNANCY
There are no available human data informing the
drug-associated risk. Advise pregnant women of
the potential risk to a foetus.
LACTATION
Opdyta 40mg Excretion in human breast milk is not
known advise women to discontinue breastfeeding
during treatment
7
CONTACT US
CALL
91-9987711567
EMAIL ID
applepharamaceutical_at_gmail.com
ADDRESS
Apartment No.304 A Wing, Shiva Shakthi chs
ltd, JP Road, Near Apna Bazar,Andheri(West),Mum
bai - 400058.Maharashtra.